Dr. Reddy's Laboratories Ltd
corporate_fare Company Profile
Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek monitors RDY SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Dr. Reddy's Acquires Key Hormone Replacement Therapy Brands in India for $32.15M
- Dr. Reddy's Global Head of IPDO Resigns, Effective May 2026
- Dr. Reddy's Reports Q3 FY26 Profitability Decline and USFDA Denosumab Biosimilar CRL
- Dr. Reddy's Q3 Profitability Declines 14% Amid Biosimilar Setbacks and Lower Lenalidomide Sales
- Dr. Reddy's Reports Significant Q3 Profit Decline Amidst Revenue Growth and Ongoing Legal/Regulatory Scrutiny
Financial Snapshot
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.